Life Sciences Tools and Services

Telesis Bio

Telesis Bio Inc. and Regeneron Enter into License Agreement

Telesis Bio released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 5,305,000 USD and EPS of -17.2309

Telesis Bio released FY2024 Q3 earnings on November 7 (EST), actual revenue $1,566,000 (forecast $2M), actual EPS -4.0938 (forecast -6.58)

Telesis Bio collaborates with Beckman Coulter Life Sciences to develop a biomanufacturing facility, leading to a significant stock price increase

Telesis Bio Inc Expects Revenue to Decline by 24.9% in Upcoming Earnings Report

Telesis Bio received delisting notice from Nasdaq

Telesis Bio released FY2023 Cumulative Q3 Earnings on November 13, 2023 (EST) with Revenue of 15.78M USD and EPS of -18.5807

The Gabelli Equity Trust Inc.

Cyclerion Therapeutics

PMGC

Axe Compute

Mega Fortune

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

System1

RYTHM

U Power

RenX Enterprises

ChromaDex

Agilent Tech

Waters

West Pharmaceutical

WuXi Biologics

Medpace

Repligen

Stevanato Group SpA

Applied DNA Sciences

Thermo Fisher Scentific

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Telesis Bio(TBIO.US)

Telesis Bio Stock Performance Chart